CEO: AstraZeneca Has ‘Winning’ Vaccine Formula

An illustration picture shows vials with COVID-19 Vaccine stickers attached and syringes, with the logo of the University of Oxford and its partner British pharmaceutical company AstraZeneca. (JUSTIN TALLIS/AFP via Getty Images)

The coronavirus vaccine developed by the British drugs group AstraZeneca and the University of Oxford has achieved a “winning formula” for efficacy, the company’s chief executive said in an interview.

The vaccine, currently being evaluated by Britain’s independent medicines regulator, provides “100 percent protection” against severe COVID-19 disease requiring hospitalization, Pascal Soriot said in an interview with the Sunday Times newspaper.

He added that he believes trials will show his firm has achieved a vaccine efficacy equal to Pfizer-BioNTech at 95% and Moderna at 94.5%.

“We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else,” Soriot said.